Medical Oncology, National Cancer Institute, Naples, Italy.
Crit Rev Oncol Hematol. 2010 Jan;73(1):23-30. doi: 10.1016/j.critrevonc.2009.08.004.
Many questions remain unanswered regarding the optimal treatment paradigm for ovarian cancer, and alternatives for both first- and second-line therapy are needed.
This review summarizes recent data with the combination of pegylated liposomal doxorubicin (PLD) and carboplatin in ovarian cancer.
Anthracyclines are active in ovarian cancer and lack the neurotoxic effects of taxanes. PLD has reduced cardiotoxic potential vs non-liposomal doxorubicin and is the only non-platinum monotherapy to demonstrate a significant survival advantage as second-line treatment of ovarian cancer. Replacing the taxane with PLD in platinum doublets for either first-line or recurrent ovarian cancer (ROC) has been or is being evaluated in more than 1600 patients. Studies evaluating PLD plus carboplatin in platinum-sensitive ROC have shown that the regimen is tolerable and active.
PLD-carboplatin is a promising chemotherapy combination. Phase III trials will elucidate whether it represents a new standard of care in ovarian cancer.
对于卵巢癌的最佳治疗方案仍存在许多未解之谜，因此需要替代一线和二线治疗方案。
本文综述了聚乙二醇脂质体阿霉素（PLD）联合卡铂治疗卵巢癌的最新数据。
蒽环类药物在卵巢癌中具有活性，且没有紫杉烷的神经毒性。PLD 的心脏毒性比非脂质体阿霉素低，并且是唯一一种作为二线治疗卵巢癌具有显著生存优势的非铂类单药。在超过 1600 名患者中，评估了将紫杉烷替换为 PLD 用于一线或复发性卵巢癌（ROC）的铂类双联化疗方案，或正在评估中。评估 PLD 联合卡铂治疗铂类敏感 ROC 的研究表明，该方案具有良好的耐受性和活性。
PLD-卡铂是一种很有前途的化疗联合方案。III 期临床试验将阐明其是否代表卵巢癌的新治疗标准。
